EUVIMEDEUVIMED entdecken
Crossref

Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study

Mauro Chiarito iD, Davide Cao iD, Samantha Sartori iD, Zhongjie Zhang, Birgit Vogel iD, Alessandro Spirito, Kenneth F Smith, William Weintraub, Craig Strauss, Catalin Toma, Anthony DeFranco, Mark B Effron und 11 weitere

European Heart Journal: Acute Cardiovascular Care · 2023

DOI: 10.1093/ehjacc/zuad083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2023. Verfasst von Mauro Chiarito und 22 weiteren Autor:innen. Beteiligte Einrichtung: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 1…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Thrombosis. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk. Methods and results PROMETHEUS was a multicentre prospective study comparing prasugrel vs. clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI). Patients were at HTR if presenting with one clinical plus one procedural risk feature. The primary endpoint was major adverse cardiac events (MACE), composite of death, myocardial infarction, stroke, or unplanned revascularization, at 1 year. Adjusted hazard ratio (adjHR) and 95% confidence intervals (CIs) were calculated with propensity score stratification and multivariable Cox regression. Among 16 065 patients, 4293 (26.7%) were at HTR and 11 772 (73.3%) at low-to-moderate thrombotic risk. The HTR conferred increased incidence of MACE (23.3 vs. 13.6%, HR 1.85, 95% CI 1.71–2.00, P < 0.001) and its single components. Prasugrel was prescribed in patients with less comorbidities and risk factors and was associated with reduced risk of MACE (HTR: adjHR 0.83, 95% CI 0.68–1.02; low-to-moderate risk: adjHR 0.75, 95% CI 0.64–0.88; pinteraction = 0.32).

Conclusion

High thrombotic risk, as defined by the 2020 ESC NSTE-ACS guidelines, is highly prevalent among ACS patients undergoing PCI. The HTR definition had a strong prognostic impact, as it successfully identified patients at increased 1 year risk of ischaemic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionThrombosisHumansClopidogrelPrasugrel HydrochloridePlatelet Aggregation InhibitorsProspective StudiesPatient DischargeTreatment Outcome

Stichwörter der Autor:innen

Acute coronary syndromeClopidogrelPrasugrelThrombotic risk

Substanzen

ClopidogrelPrasugrel HydrochloridePlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.
  • Cardio Center, Humanitas Clinical and Research Hospital IRCCS, Via Alessandro Manzoni, 56, 20089 Rozzano, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, Pieve Emanuele, Milan, Italy.
  • Division of Cardiology, Christiana Care Health System, 313 W Main St, Newark, DE 19711, USA.
  • Division of Cardiology, Minneapolis Heart Institute, 920 E 28th St #100, Minneapolis, MN 55407, USA.
  • Division of Cardiology, University of Pittsburgh Medical Center, 200 Meyran Ave # 318, Pittsburgh, PA 15213, USA.

ORCID-Profile: Mauro Chiarito, Davide Cao, Samantha Sartori, Birgit Vogel, Roxana Mehran

Zitieren

APA

Chiarito, M., Cao, D., Sartori, S., Zhang, Z., Vogel, B., Spirito, A., Smith, K. F., Weintraub, W., Strauss, C., Toma, C., DeFranco, A., Effron, M. B., Stefanini, G., Keller, S., Kapadia, S., Rao, S. V., Henry, T. D., Pocock, S., Sharma, S., …, & Mehran, R. (2023). Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuad083

Vancouver

Chiarito M, Cao D, Sartori S, Zhang Z, Vogel B, Spirito A, et al. Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study. European Heart Journal: Acute Cardiovascular Care. 2023. doi:10.1093/ehjacc/zuad083

BibTeX
@article{Chiarito2023,
  author = {Chiarito, Mauro and Cao, Davide and Sartori, Samantha and Zhang, Zhongjie and Vogel, Birgit and Spirito, Alessandro and Smith, Kenneth F and Weintraub, William and Strauss, Craig and Toma, Catalin and DeFranco, Anthony and Effron, Mark B and Stefanini, Giulio and Keller, Stuart and Kapadia, Samir and Rao, Sunil V and Henry, Timothy D and Pocock, Stuart and Sharma, Samin and Dangas, George and Kini, Annapoorna and Baber, Usman and Mehran, Roxana},
  title = {Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2023},
  doi = {10.1093/ehjacc/zuad083}
}
Kostenlos starten →